Stroke in Mechanical Circulatory Supported Cardiogenic Shock

Victor Galusko; Vasileios Panoulas; Diana A. Gorog; Christophe Vandenbriele

doi:10.1055/a-2697-3309

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost
DOI: 10.1055/a-2697-3309

Review Article

Stroke in Mechanical Circulatory Supported Cardiogenic Shock

Authors

Victor Galusko

¹Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom

²Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom
Vasileios Panoulas

¹Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom

²Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom
Diana A. Gorog

¹Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom

²Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom

³School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, Hatfield, Hertfordshire, United Kingdom
Christophe Vandenbriele

¹Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom

⁴Department of Cardiology and Cardiac Intensive Care, Heart Center Aalst, Aalst, Belgium

⁵Department of Cancer and Surgery, Imperial College, London, United Kingdom

Abstract

Stroke is a devastating and underdiagnosed complication in patients with cardiogenic shock (CS) supported by temporary mechanical circulatory support (tMCS). Stroke occurs in approximately 1 to 4% of patients on microaxial flow pumps and 6 to 7% of those on veno-arterial extracorporeal membrane oxygenation, though the true incidence is likely higher due to diagnostic limitations in sedated and critically ill patients. The occurrence of stroke in this population significantly worsens clinical outcomes, increasing morbidity, mortality, and healthcare resource utilization. This review outlines the risk factors and mechanisms underlying both ischaemic and haemorrhagic stroke in patients receiving tMCS. It explores how the aetiology of CS, the choice of tMCS device, anticoagulation strategies, and cellular injury contribute to stroke risk. The pathophysiology in this setting is multifactorial and often dual-edged, driven by haemolysis, platelet dysfunction, endothelial disruption, and immune-mediated thrombogenesis. Concurrently, bleeding complications arise from acquired von Willebrand syndrome, thrombocytopenia, and dysregulated fibrinolysis. Currently, there are no evidence-based guidelines for managing bleeding and thrombotic complications in patients on tMCS, largely due to the lack of robust data. Consequently, clinical practices vary, and treatment decisions often require navigating a complex balance between thrombosis and bleeding without high-quality evidence to guide care. This review highlights the key physiological and pathological changes associated with tMCS to inform strategies for stroke prevention, early detection, and management. Developing standardised protocols through prospective studies is essential to improving outcomes in this high-risk population.

Keywords

cardiogenic shock - mechanical circulatory support - stroke

Full Text

References

References
1 van Diepen S, Katz JN, Albert NM. et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017; 136 (16) e232-e268
2 Møller JE, Engstrøm T, Jensen LO. et al; DanGer Shock Investigators. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med 2024; 390 (15) 1382-1393
3 Lüscher TF, Thiele H. Cardiogenic shock: do we need a paradigm shift?. Eur Heart J 2024; 45 (39) 4178-4180
4 Thiele H, Zeymer U, Akin I. et al; ECLS-SHOCK Investigators. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med 2023; 389 (14) 1286-1297
5 Hwang J, Kalra A, Shou BL. et al. Epidemiology of ischemic stroke and hemorrhagic stroke in venoarterial extracorporeal membrane oxygenation. Crit Care 2023; 27 (01) 433
6 Pahuja M, Chehab O, Ranka S. et al. Incidence and clinical outcomes of stroke in ST-elevation myocardial infarction and cardiogenic shock. Catheter Cardiovasc Interv 2021; 97 (02) 217-225
7 Rastan AJ, Lachmann N, Walther T. et al. Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs 2006; 29 (12) 1121-1131
8 Levy JH, Alexander PMA, Wolberg AS. et al. ECMO-induced coagulopathy: strategic initiatives for research and clinical practice (a workshop report of the NHLBI). Blood Vessel Thromb Hemost 2025; 2 (02) 100064
9 Pacheco-Reyes AF, Plata-Menchaca EP, Mera A. et al. Coagulation management in patients requiring extracorporeal membrane oxygenation support: a comprehensive narrative review. Ann Blood 2024; 9
10 Bae DJ, Willey JZ, Ibeh C, Yuzefpolskaya M, Colombo PC. Stroke and mechanical circulatory support in adults. Curr Cardiol Rep 2023; 25 (12) 1665-1675
11 Stone GW, Ohman EM, Miller MF. et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol 2003; 41 (11) 1940-1945
12 Thiele H, Zeymer U, Neumann F-J. et al; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367 (14) 1287-1296
13 Motia N, Marko V, Karlsen MW. Complications associated with intra-aortic balloon pump treatment in critically ill patients: a systematic review. Nurs Crit Care 2024; 29 (06) 1768-1780
14 Ouweneel DM, de Brabander J, Karami M. et al. Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. Eur Heart J Acute Cardiovasc Care 2019; 8 (04) 338-349
15 Saito Y, Tateishi K, Toda K, Matsumiya G, Kobayashi Y. J-PVAD registry study investigators. Complications and outcomes of Impella treatment in cardiogenic shock patients with and without acute myocardial infarction. J Am Heart Assoc 2023; 12 (17) e030819
16 Ramzy D, Anderson M, Batsides G. et al. Early outcomes of the first 200 US Patients treated with Impella 5.5: a novel temporary left ventricular assist device. Innovations (Phila) 2021; 16 (04) 365-372
17 Rock JR, Kos CA, Lemaire A. et al. Single center first year experience and outcomes with Impella 5.5 left ventricular assist device. J Cardiothorac Surg 2022; 17 (01) 124
18 Le Guennec L, Cholet C, Huang F. et al. Ischemic and hemorrhagic brain injury during venoarterial-extracorporeal membrane oxygenation. Ann Intensive Care 2018; 8 (01) 129
19 Cho SM, Canner J, Caturegli G. et al. Risk factors of ischemic and hemorrhagic strokes during venovenous extracorporeal membrane oxygenation: analysis of data from the Extracorporeal Life Support Organization Registry. Crit Care Med 2021; 49 (01) 91-101
20 Cho SM, Canner J, Chiarini G. et al. Modifiable risk factors and mortality from ischemic and hemorrhagic strokes in patients receiving venoarterial extracorporeal membrane oxygenation: results from the Extracorporeal Life Support Organization Registry. Crit Care Med 2020; 48 (10) e897-e905
21 Schrage B, Becher PM, Bernhardt A. et al. Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: results from an international, multicenter cohort study. Circulation 2020; 142 (22) 2095-2106
22 Yan R, Yang J, Shi B. et al. Risk of acute ischemic stroke with early versus late initiation of mechanical circulatory support in hospitalizations with acute myocardial infarction complicated by cardiogenic shock: a propensity-matched analysis. BMC Cardiovasc Disord 2025; 25 (01) 372
23 Barrionuevo-Sánchez MI, Ariza-Solé A, Prado ND. et al. Impact of shock aetiology and hospital characteristics on the clinical profile, management and prognosis of patients with non ACS-related cardiogenic shock. Hellenic J Cardiol 2023; 69: 16-23
24 Noda K, Koga M, Toyoda K. Recognition of strokes in the ICU: a narrative review. J Cardiovasc Dev Dis 2023; 10 (04) 182
25 Jo S, Chang JY, Jeong S, Jeong S, Jeon SB. Newly developed stroke in patients admitted to non-neurological intensive care units. J Neurol 2020; 267 (10) 2961-2970
26 Schupp T, Forner J, Rusnak J. et al. Does atrial fibrillation deteriorate the prognosis in patients with septic or cardiogenic shock?. Am J Cardiol 2023; 205: 141-149
27 de Waha S, Schoene K, Fuernau G. et al. Prognostic impact of atrial fibrillation in cardiogenic shock complicating acute myocardial infarction: a substudy of the IABP-SHOCK II trial. Clin Res Cardiol 2018; 107 (03) 233-240
28 Deng RM, Liu YC, Li JQ, Xu JG, Chen G. The role of carbon dioxide in acute brain injury. Med Gas Res 2020; 10 (02) 81-84
29 Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch 2007; 454 (03) 345-359
30 Alphonsus CS, Rodseth RN. The endothelial glycocalyx: a review of the vascular barrier. Anaesthesia 2014; 69 (07) 777-784
31 Coster JN, Noda K, Ryan JP. et al. Effects of intraoperative support strategies on endothelial injury and clinical lung transplant outcomes. Semin Thorac Cardiovasc Surg 2024; 36 (03) 358-368
32 Chen X, Geng X, Jin S. et al. The Association of Syndecan-1, hypercoagulable state and thrombosis and in patients with nephrotic syndrome. Clin Appl Thromb Hemost 2021; 27: 10 760296211010256
33 Horvath B, Hegedus D, Szapary L. et al. Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases. Exp Clin Cardiol 2004; 9 (01) 31-34
34 Ernofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 1997; 113 (03) 576-584
35 Doyle AJ, Hunt BJ. Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components. Front Med (Lausanne) 2018; 5: 352
36 Vandenbriele C, Vanassche T, Price S. Why we need safer anticoagulant strategies for patients on short-term percutaneous mechanical circulatory support. Intensive Care Med 2020; 46 (04) 771-774
37 Zhou Y, Qin S, Hilton T. et al. Quantification of Von Willebrand factor cleavage by ADAMTS-13 in patients supported by left ventricular assist devices. ASAIO J 2017; 63 (06) 849-853
38 Staessens S, Moussa MD, Pierache A. et al. Thrombus formation during ECMO: Insights from a detailed histological analysis of thrombus composition. J Thromb Haemost 2022; 20 (09) 2058-2069
39 Hastings SM, Deshpande SR, Wagoner S, Maher K, Ku DN. Thrombosis in centrifugal pumps: location and composition in clinical and in vitro circuits. Int J Artif Organs 2016; 39 (04) 200-204
40 Hastings SM, Ku DN, Wagoner S, Maher KO, Deshpande S. Sources of circuit thrombosis in pediatric extracorporeal membrane oxygenation. ASAIO J 2017; 63 (01) 86-92
41 Bannan S, Danby A, Cowan D, Ashraf S, Gesinde M, Martin P. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model. Eur J Cardiothorac Surg 1997; 12 (02) 268-275
42 Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM. Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb 1991; 11 (06) 1700-1711
43 Lin T, Kwak YH, Sammy F. et al. Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin. J Infect Dis 2010; 202 (04) 624-632
44 Tran PL, Pietropaolo M-G, Valerio L. et al. Hemolysate-mediated platelet aggregation: an additional risk mechanism contributing to thrombosis of continuous flow ventricular assist devices. Perfusion 2016; 31 (05) 401-408
45 Frere C, Mazzeffi M, Maier CL. et al. Acquired von Willebrand syndrome during extracorporeal membrane oxygenation support: a comprehensive review of current evidence: communication from the ISTH SSC on perioperative and critical care thrombosis and hemostasis. J Thromb Haemost 2024; 22 (09) 2608-2628
46 Hanson E, Jood K, Nilsson S, Blomstrand C, Jern C. Association between genetic variation at the ADAMTS13 locus and ischemic stroke. J Thromb Haemost 2009; 7 (12) 2147-2148
47 Saeed O, Jakobleff WA, Forest SJ. et al. Hemolysis and nonhemorrhagic stroke during venoarterial extracorporeal membrane oxygenation. Ann Thorac Surg 2019; 108 (03) 756-763
48 Cowger JA, Romano MA, Shah P. et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant 2014; 33 (01) 35-43
49 Omar HR, Mirsaeidi M, Socias S. et al. Plasma free hemoglobin is an independent predictor of mortality among patients on extracorporeal membrane oxygenation support. PLoS One 2015; 10 (04) e0124034
50 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13 (03) 269-288
51 Ridger VC, Boulanger CM, Angelillo-Scherrer A. et al; Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. Microvesicles in vascular homeostasis and diseases. Thromb Haemost 2017; 117 (07) 1296-1316
52 Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011; 31 (01) 15-26
53 Siegel PM, Hentschel D, Bojti I. et al. Annexin V positive microvesicles are elevated and correlate with flow rate in patients receiving veno-arterial extracorporeal membrane oxygenation. Interact Cardiovasc Thorac Surg 2020; 31 (06) 884-891
54 Chandler WL. Platelet, red cell, and endothelial activation and injury during extracorporeal membrane oxygenation. ASAIO J 2021; 67 (08) 935-942
55 Diehl P, Aleker M, Helbing T. et al. Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation. Interact Cardiovasc Thorac Surg 2010; 11 (02) 133-137
56 Nascimbene A, Hernandez R, George JK. et al. Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transplant 2014; 33 (05) 470-477
57 Gupta A, Karakas C, Sukru A, Elnazeir M. Hemorrhagic complications of unfractionated heparin in adult patients with acute ischemic stroke: prevalence and risk factors (P2–5.012). Neurology 2024; 102 (07) 2690
58 Adams JA. Endothelium and cardiopulmonary resuscitation. Crit Care Med 2006; 34 (12, suppl): S458-S465
59 Cerchiari EL, Safar P, Klein E, Diven W. Visceral, hematologic and bacteriologic changes and neurologic outcome after cardiac arrest in dogs. The visceral post-resuscitation syndrome. Resuscitation 1993; 25 (02) 119-136
60 Neumar RW, Nolan JP, Adrie C. et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. Circulation 2008; 118 (23) 2452-2483
61 Engström M, Schött U, Romner B, Reinstrup P. Acidosis impairs the coagulation: a thromboelastographic study. J Trauma 2006; 61 (03) 624-628
62 Rossaint R, Afshari A, Bouillon B. et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care 2023; 27 (01) 80
63 Wallner B, Schenk B, Hermann M. et al. Hypothermia-associated coagulopathy: a comparison of viscoelastic monitoring, platelet function, and real time live confocal microscopy at low blood temperatures, an in vitro experimental study. Front Physiol 2020; 11: 843
64 Vallabhajosyula S, Dunlay SM, Prasad A. et al. Acute noncardiac organ failure in acute myocardial infarction with cardiogenic shock. J Am Coll Cardiol 2019; 73 (14) 1781-1791
65 Masi P, Gendreau S, Moyon Q. et al. Bleeding complications, coagulation disorders, and their management in acute myocardial infarction-related cardiogenic shock rescued by veno-arterial ECMO: A retrospective cohort study. J Crit Care 2024; 82: 154771
66 Oyabu K, Hattori H, Kikuchi N. et al. Cardiogenic shock severity predicts bleeding events in patients with temporary mechanical circulatory support. Catheter Cardiovasc Interv 2024; 104 (07) 1508-1516
67 Freund A, Jobs A, Lurz P. et al. Frequency and impact of bleeding on outcome in patients with cardiogenic shock. JACC Cardiovasc Interv 2020; 13 (10) 1182-1193
68 Valladolid C, Yee A, Cruz MA. von Willebrand Factor, free hemoglobin and thrombosis in ECMO. Front Med (Lausanne) 2018; 5: 228
69 Panholzer B, Bajorat T, Haneya A. et al. Acquired von Willebrand syndrome in ECMO patients: A 3-year cohort study. Blood Cells Mol Dis 2021; 87: 102526
70 Flierl U, Tongers J, Berliner D. et al. Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. PLoS One 2017; 12 (08) e0183193
71 Mehra MR, Goldstein DJ, Cleveland JC. et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA 2022; 328 (12) 1233-1242
72 Wever-Pinzon O, Selzman CH, Drakos SG. et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 2013; 6 (03) 517-526
73 Vincent F, Rauch A, Loobuyck V. et al. Arterial pulsatility and circulating von Willebrand factor in patients on mechanical circulatory support. J Am Coll Cardiol 2018; 71 (19) 2106-2118
74 Jiritano F, Serraino GF, Ten Cate H. et al. Platelets and extra-corporeal membrane oxygenation in adult patients: a systematic review and meta-analysis. Intensive Care Med 2020; 46 (06) 1154-1169
75 Klaeske K, Dieterlen MT, Eifert S. et al. Device-induced platelet dysfunction in patients after left ventricular assist device implantation. J Thromb Haemost 2021; 19 (05) 1331-1341
76 Houry EA, Gengler BE, Alberts JL, Van Tuyl JS. Evaluation of thrombocytopenia in patients receiving percutaneous mechanical circulatory support with an Impella device. Crit Care Explor 2022; 4 (10) e0772
77 Raasveld SJ, van den Oord C, Schenk J. et al. The interaction of thrombocytopenia, hemorrhage, and platelet transfusion in venoarterial extracorporeal membrane oxygenation: a multicenter observational study. Crit Care 2023; 27 (01) 321
78 Milwidsky A, Haroun M, Saeed O. et al. Post left ventricular assist device implantation platelets count alterations are related to gender, race and early mortality. J Heart Lung Transplant 2021; 40 (4, suppl): S400
79 Huang Z, Liu C, Wu Z. et al. Elevated platelet count is associated with decreased mortality from hemorrhagic stroke in hospital: a multi-center retrospective cohort study. Sci Rep 2024; 14 (01) 3797
80 Collins Yoder AS, Hines CB. Thrombocytopenia: effect in ischemic and hemorrhagic stroke. Dimens Crit Care Nurs 2021; 40 (03) 139-148
81 Chen Z, Mondal NK, Ding J, Gao J, Griffith BP, Wu ZJ. Shear-induced platelet receptor shedding by non-physiological high shear stress with short exposure time: glycoprotein Ibα and glycoprotein VI. Thromb Res 2015; 135 (04) 692-698
82 Siegel PM, Chalupsky J, Olivier CB. et al. Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality. J Thromb Thrombolysis 2022; 53 (03) 712-721
83 Kalbhenn J, Schlagenhauf A, Rosenfelder S, Schmutz A, Zieger B. Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation: rapid onset and fast recovery. J Heart Lung Transplant 2018; 37 (08) 985-991
84 Marquardt L, Ruf A, Mansmann U. et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33 (11) 2570-2574
85 Balle CM, Jeppesen AN, Christensen S, Hvas AM. Platelet function during extracorporeal membrane oxygenation in adult patients. Front Cardiovasc Med 2019; 6: 114
86 Helms J, Curtiaud A, Severac F. et al. Fibrinolysis as a causative mechanism for bleeding complications on extracorporeal membrane oxygenation: a pilot observational prospective study. Anesthesiology 2024; 141 (01) 75-86
87 Kanou S, Nakatani E, Urano T. et al; Study of Advanced life support for Ventricular fibrillation with Extracorporeal circulation in Japan (SAVE-J II) Study Group. Fibrinogen levels and bleeding risk in adult extracorporeal cardiopulmonary resuscitation: multicenter observational study subanalysis. Res Pract Thromb Haemost 2025; 9 (02) 102700
88 Romoli M, Vandelli L, Bigliardi G. et al. Fibrinogen depletion coagulopathy predicts major bleeding after thrombolysis for ischemic stroke: a multicenter study. Stroke 2022; 53 (12) 3671-3678
89 Ribo M, Montaner J, Molina CA. et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004; 35 (09) 2123-2127
90 Doyle AJ, Retter A, Parmar K. et al. Temporal changes in markers of coagulation and fibrinolysis in adults during extracorporeal membrane oxygenation. Perfusion 2025; 40 (04) 984-992
91 Rilinger JF, Smith CM, deRegnier RAO. et al. Transcranial doppler identification of neurologic injury during pediatric extracorporeal membrane oxygenation therapy. J Stroke Cerebrovasc Dis 2017; 26 (10) 2336-2345
92 Zhang H, Xu J, Yang X. et al. Narrative review of neurologic complications in adults on ECMO: prevalence, risks, outcomes, and prevention strategies. Front Med (Lausanne) 2021; 8: 713333
93 Hunt MF, Clark KT, Whitman G, Choi CW, Geocadin RG, Cho SM. The use of cerebral NIRS monitoring to identify acute brain injury in patients with VA-ECMO. J Intensive Care Med 2021; 36 (12) 1403-1409
94 Johnston SC, Amarenco P, Denison H. et al; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020; 383 (03) 207-217
95 Gorog DA, Combes A. Antithrombotic management during percutaneous mechanical circulatory support: defining the status quo, before agreeing quo vadis. Eur Heart J Acute Cardiovasc Care 2024; 13 (06) 470-471
96 Van Edom CJ, Swol J, Castelein T. et al. European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization. Eur Heart J Acute Cardiovasc Care 2024; 13 (06) 458-469
97 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349 (9065): 1569-1581
98 Jazayeri SB, Ghozy S, Saha R, Gajjar A, Elfil M, Kallmes DF. Reevaluating the role of heparin during mechanical thrombectomy for acute ischemic stroke: Increased risks without functional benefit. Clin Neurol Neurosurg 2024; 246: 108560
99 Zhang X, Zhong W, Xue R. et al. Argatroban in patients with acute ischemic stroke with early neurological deterioration: a randomized clinical trial. JAMA Neurol 2024; 81 (02) 118-125
100 Sukumaran M, Cantrell DR, D'Agostino C, Jahromi BS, Ansari SA, Potts MB. Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia. J Stroke Cerebrovasc Dis 2024; 33 (06) 107310
101 Werring DJ, Dehbi H-M, Ahmed N. et al; OPTIMAS investigators. Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial. Lancet 2024; 404 (10464): 1731-1741
102 To L, Attar D, Lines B. et al. Incidence of heparin-induced thrombocytopenia in patients with newly implanted mechanical circulatory support devices. Ann Pharmacother 2022; 56 (05) 565-571
103 Iacobelli R, Fletcher-Sandersjöö A, Lindblad C, Keselman B, Thelin EP, Broman LM. Predictors of brain infarction in adult patients on extracorporeal membrane oxygenation: an observational cohort study. Sci Rep 2021; 11 (01) 3809
104 Van Edom C, Fiorelli F, Balthazar T. et al. Dual guided heparin monitoring with anti-Xa and APTT during micro-axial flow pump support for cardiogenic shock. Eur Heart J 2024; 45 (01) 1758
105 Vandenbriele C, Mueller T, Patel B. Consumptive coagulopathy: how low-dose unfractionated heparin can prevent bleeding complications during extracorporeal life support. Intensive Care Med 2024; 50 (08) 1358-1360
106 Kohli G, George DD, Grenga A. et al. Mechanical thrombectomy for ischemic stroke secondary to large vessel occlusions in patients on extracorporeal membrane oxygenation. Cerebrovasc Dis 2023; 52 (05) 532-538
107 Le Guennec L, Schmidt M, Clarençon F. et al. Mechanical thrombectomy in acute ischemic stroke patients under venoarterial extracorporeal membrane oxygenation. J Neurointerv Surg 2020; 12 (05) 486-488
108 Krenzlin H, Rosenthal C, Wolf S. et al. Surgical treatment of intraparenchymal hemorrhage during mechanical circulatory support for heart-failure–a single-centre experience. Acta Neurochir (Wien) 2014; 156 (09) 1729-1734
109 Factora FN, Bustamante S, Spiotta A, Avitsian R. Intracranial hemorrhage surgery on patients on mechanical circulatory support: a case series. J Neurosurg Anesthesiol 2011; 23 (01) 30-34
110 Angiolillo DJ, Capodanno D. Uncoupling thrombosis and hemostasis by inhibiting factor XI. N Engl J Med 2025; 392 (04) 400-403